16 / 18
Inst itut Català d'Oncologia
Institut Català d’Oncol gia
•
Fast progressors (FP)
•
Progression in <2 months + fast clinical deterioration
•
n=18 (26%)
•
ECOG PS 0–1 at baseline: 94% → ECOG PS 3 at progression:
72%
•
Long-term responders (LR)
• Time to treatment failure >6 months
•
n=9 (13%)
Factor
FP
n (%)
No FP
n (%)
p
PD-L1 positive (n=26)
6 (33) 20 (59)
0.2
IM-CT (n=5)
0 (0) 5 (15)
0.1
“Bulky disease” (n=25)
11 (59) 14 (41)
0.1
Tumoural complication (n=15) 10 (55) 5 (15)
0.03
Platinum resistance (<6
month)
(
n=28)
12 (81) 16 (47)
0.1
Neutrophil count
60980
(SD
813)
5177
(SD
418)
0.03
Factor
n=
9
Factor
n=9
Tumoral
response
CR
PR
SD
2
4
3
Treatment:
Anti-PD-1 / PD-L1
IMD
IM-CT
4
1
4
Line
1
st
2
nd
3/4
th
5
4
0
PD-L1:
Positive
Negative
Unknown
7
1
1
•
Survival (95% CI)
LR
15 mo (5.9–24)
No-LR
4 mo (2.6–5.3)
•
HR 0.4 (0.8–2); p=0.2
•Log-Rank p
=
0.03
•1.0
•0.8
•0.6
•0.4
•0.4
•0.0
•Cumulative survival
•0 •5 •10 •15 •20 •25 •30
•Time (months)
•
Median OS (95% CI)
No-FP
14 mo (8.6–20)
FP
2 mo (1.2–2.0)
HR 5.6 (2.7–12); p=0.001
•Log-rank p
=
0.02
•1.0
•0.8
•0.6
•0.4
•0.4
•0.0
•Cumulative survival
•0 •5 •10 •15 •20 •25 •30
•Time (months)
Results: long-term survivors versus fast progressors
Ortega A, et al. SEOM 2017